• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Chronic lymphocytic leukemia in 2020: a surfeit of riches?2020年的慢性淋巴细胞白血病：是资源过剩吗？
Leukemia. 2020 Aug;34(8):1979-1983. doi: 10.1038/s41375-020-0852-7. Epub 2020 May 11.
2
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者对布鲁顿酪氨酸激酶（BTK）抑制剂耐药的机制
Clin Adv Hematol Oncol. 2021 Jul;19(7):436-438.
3
Current Perspectives on Therapy for Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病治疗的当前观点
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-10. doi: 10.1200/EDBK_279099.
4
BTK Inhibitors and Chemoimmunotherapy for CLL.布鲁顿酪氨酸激酶抑制剂与慢性淋巴细胞白血病的化学免疫疗法
Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S22-S24. doi: 10.1016/S2152-2650(20)30449-3.
5
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.布鲁顿酪氨酸激酶和CD52双重靶向治疗可使预后不良的慢性淋巴细胞白血病患者骨髓中的微小残留病转阴，但与机会性感染相关——一项I期研究的结果
Br J Haematol. 2018 Aug;182(4):590-594. doi: 10.1111/bjh.14836. Epub 2017 Jul 5.
6
Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday.限时联合治疗方案在慢性淋巴细胞白血病中的应用：实现药物假期的有前途策略。
Curr Med Sci. 2021 Jun;41(3):431-442. doi: 10.1007/s11596-021-2385-3. Epub 2021 Jun 28.
7
Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.泽布替尼：一种用于慢性淋巴细胞白血病和非霍奇金淋巴瘤的新型布鲁顿酪氨酸激酶抑制剂。
Clin Adv Hematol Oncol. 2019 Jan;17(1):32-34.
8
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.初治 CLL：来自 2 期和 3 期临床试验的经验。
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):476-481. doi: 10.1182/hematology.2019001321.
9
Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.解析慢性淋巴细胞白血病中依鲁替尼耐药性
J Clin Oncol. 2017 May 1;35(13):1451-1452. doi: 10.1200/JCO.2016.72.0102. Epub 2017 Mar 14.
10
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.阿卡拉布替尼联合奥滨尤妥珠单抗治疗初治及复发/难治性慢性淋巴细胞白血病
Cancer Discov. 2020 Mar;10(3):394-405. doi: 10.1158/2159-8290.CD-19-1130. Epub 2020 Jan 8.

引用本文的文献

1
Development of a modular patient-reported outcome and experience measure on patient needs and benefits in CLL (PBI-CLL).关于慢性淋巴细胞白血病患者需求与获益的模块化患者报告结局与体验测量工具（PBI-CLL）的开发。
J Patient Rep Outcomes. 2025 Apr 29;9(1):45. doi: 10.1186/s41687-025-00882-5.
2
Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.分析慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂临床试验的挑战。
Leukemia. 2024 Jul;38(7):1469-1473. doi: 10.1038/s41375-024-02294-8. Epub 2024 Jun 1.
3
Zanubrutinib: past, present, and future.泽布替尼：过去、现在和未来。
Blood Cancer J. 2023 Sep 11;13(1):141. doi: 10.1038/s41408-023-00902-x.
4
Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?新药会取代慢性淋巴细胞白血病的移植治疗吗？
J Clin Med. 2021 Jun 7;10(11):2516. doi: 10.3390/jcm10112516.

本文引用的文献

1
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.Binet 分期 A 期初诊 CLL 患者的预后模型：德国 CLL 研究组多中心前瞻性 CLL1 试验的结果。
Leukemia. 2020 Apr;34(4):1038-1051. doi: 10.1038/s41375-020-0727-y. Epub 2020 Feb 10.
2
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
3
Machine learning can identify newly diagnosed patients with CLL at high risk of infection.机器学习可以识别新诊断出的 CLL 患者中感染风险较高的患者。
Nat Commun. 2020 Jan 17;11(1):363. doi: 10.1038/s41467-019-14225-8.
4
Phosphatidylinositol 3 Kinase δ Inhibitors: Present and Future.磷脂酰肌醇 3 激酶 δ 抑制剂：现状与未来。
Cancer J. 2019 Nov/Dec;25(6):394-400. doi: 10.1097/PPO.0000000000000414.
5
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
6
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.维奈托克联合奥滨尤妥珠单抗治疗伴有合并症的 CLL 患者
N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.
7
Ibrutinib and Venetoclax for First-Line Treatment of CLL.伊布替尼联合维奈托克用于初治 CLL 患者。
N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.
8
New roles for B cell receptor associated kinases: when the B cell is not the target.BCR 相关激酶的新作用：当 B 细胞不是靶点时。
Leukemia. 2019 Mar;33(3):576-587. doi: 10.1038/s41375-018-0366-8. Epub 2019 Jan 30.
9
Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.慢性淋巴细胞白血病患者血流感染的流行病学：一项纵向全国队列研究。
Leukemia. 2019 Mar;33(3):662-670. doi: 10.1038/s41375-018-0316-5. Epub 2018 Dec 13.
10
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.复发性 Gly101Val 突变的获得使慢性淋巴细胞白血病患者对 Venetoclax 产生耐药性。
Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.

Chronic lymphocytic leukemia in 2020: a surfeit of riches?

作者信息

Parikh Sameer A, Gale Robert Peter, Kay Neil E

机构信息

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, UK.

出版信息

Leukemia. 2020 Aug;34(8):1979-1983. doi: 10.1038/s41375-020-0852-7. Epub 2020 May 11.

DOI:10.1038/s41375-020-0852-7
PMID:32393844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8130839/
Abstract
摘要